Clinical Outcomes of Patients with EGFR T790M+NSCLC on Osimertinib

被引：0
|
作者：
Tan, W. L. [1 ]
Hennedige, T. P. [2 ]
Ng, Q. S. [3 ]
Tan, S. H. [4 ]
Tran, N. T. A. [5 ]
Chua, B. J. G. [6 ]
Toh, C. K. [3 ]
Tan, E. H. [3 ]
Tan, D. [3 ]
Ang, M. [3 ]
Kanesvaran, R. [3 ]
Jain, A. [3 ]
Lim, T. K. H. [7 ]
Gogna, A. [8 ]
Koh, M. [9 ]
Yip, C. S. P. [10 ]
Thng, C. H. [2 ]
Chowbay, B. [11 ]
Tan, M. H. [3 ]
Lim, W. [3 ]
机构：
[1] Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore
[2] Natl Canc Ctr Singapore, Oncol Imaging, Singapore, Singapore
[3] Natl Canc Ctr, Med Oncol, Singapore, Singapore
[4] Natl Canc Ctr Singapore, Clin Trial Off, Singapore, Singapore
[5] Moh Holdings, Diagnost Radiol, Singapore, Singapore
[6] Moh Holdings, Singapore, Singapore
[7] Singhealth, Anat Pathol, Singapore, Singapore
[8] Singhealth, Diagnost Radiol, Singapore, Singapore
[9] Singhealth, Pulmonol, Singapore, Singapore
[10] Natl Canc Ctr Singapore, Radiat Oncol, Singapore, Singapore
[11] Natl Canc Ctr Singapore, Med Sci & Clin Pharmacol, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR T790M; osimertinib; NSCLC;
D O I：
10.1016/j.jtho.2017.09.1458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-017
引用
收藏
页码：S2206 / S2206
页数：1
相关论文
共 50 条
  • [21] EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
    Zheng, Qiufan
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hong, Shaodong
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 471 - +
  • [22] Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation
    Yoshimura, Naruo
    Takahashi, Hidenori
    Kurosawa, Emiko
    Tanaka, Akiko
    Ebina, Masahito
    Ohrui, Takashi
    ANNALS OF ONCOLOGY, 2019, 30 : 139 - 139
  • [23] ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
    Freitas, H. C.
    Park, K.
    Kim, D-W.
    Tiseo, M.
    Hochmair, M. J.
    Chang, G-C.
    Shi, Y-K.
    Moran, T.
    Chen, Y.
    Laskin, J.
    Solomon, B.
    Miranda, M.
    Rigas, J.
    Cheema, P. K.
    Kim, S-W.
    ANNALS OF ONCOLOGY, 2018, 29 : 149 - 149
  • [24] A Phase II Study of Osimertinib versus Combination of Osimertinib and Chemotherapy for EGFR and T790M-Mutation Positive NSCLC
    Mouri, A.
    Tanaka, K.
    Asahina, H.
    Kishimoto, J.
    Okada, M.
    Watanabe, K.
    Hamai, K.
    Harada, T.
    Tsubata, Y.
    Sugawara, S.
    Kobayashi, K.
    Sugio, K.
    Oizumi, S.
    Okamoto, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S226 - S227
  • [25] Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
    Schmid, S.
    Klingbiel, D.
    Aeppli, S.
    Britschgi, C.
    Gautschi, O.
    Pless, M.
    Rothschild, S.
    Wannesson, L.
    Janthur, W.
    Foerbs, D.
    Demmer, I.
    Jochum, W.
    Fruth, M.
    LUNG CANCER, 2019, 130 : 149 - 155
  • [26] Real-world outcomes of osimertinib in Peruvian patients with advanced NSCLC with EGFR T790M-positive: A multi-institutional experience
    Galvez-Nino, Marco
    Roque, Katia
    Namuche, Fernando
    Ruiz, Rossana
    Paitan Amaro, Victor
    Coello, Roberto
    del Pilar Cabrera, Maria
    Maco, Lorenzo
    Carlos Ezquerra, Juan
    Perez Roca, Rodolfo
    Coanqui, Ofelia
    Valdivieso, Natalia
    Olivera Hurtado de Mendoza, Mivael
    Aguilar Cartagena, Alfredo
    Mas, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC
    Paz-Ares, L.
    Planchard, D.
    Yang, J. C.
    Lee, K.
    Garrido, P.
    Park, K. K.
    Kim, J.
    Lee, D. H.
    Mao, H.
    Chao, B.
    Yu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S453 - S454
  • [28] EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
    Hochmair, Maximilian J.
    Holzer, Sophia
    Filipits, Martin
    Mohn-Staudner, Andrea
    Arns, Madeleine
    Errhalt, Peter
    Absenger, Gudrun
    Koller-Herzog, Ursula
    Setinek, Ulrike
    Haslbauer, Ferdinand
    Korger, Mark A.
    Patocka, Kurt
    Kolb, Rainer
    Burghuber, Otto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
    Hochmair, Maximilian
    Holzer, Sophia
    Filipits, Martin
    Mohn-Staudner, Andrea
    Errhalt, Peter
    Absenger, Gudrun
    Bundalo, Tatjana
    Arns, Madeleine
    Setinek, Ulrike
    Mikes, Romana
    Kolb, Rainer
    Schumacher, Michael
    Zoechbauer-Mueller, Sabine
    Patocka, Kurt
    Haslbauer, Ferdinand
    Rudzki, Jakob
    Burghuber, Otto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1254
  • [30] Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study)
    Xing, L.
    Pan, Y.
    Shi, Y.
    Shu, Y.
    Feng, J.
    Li, W.
    Cao, L.
    Wang, L.
    Gu, W.
    Song, Y.
    Yu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
12345